Parameters Control Cholesterol-fed non-treated Cholesterol-fed Aliskiren-treated
SOD (IU/mL) 22 ± 3.2 0.9 ± 0.01* 45.3±5.6**
SBP (mmHg) 100 ± 5.7 158 ± 3.4* 90.5 ± 3.2**
TC (mg/dL) 65.53 ± 5.43 255.4 ± 13.22* 45.76 ± 3.44**
relaxation of aortic basal tone 66.14 ± 12.16 87.43 ± 6.0* 48.10 ± 10.23**
 % mean relaxation of aortic basal tone from control group   +32.19% -27.28%
% mean relaxation of aortic basal tone from cholesterol-fed non-treated group     -44.98%
Table 1 showed the results recorded at the end of 12th week therapy by aliskiren regarding SOD enzyme in RBCs lysates, SBP, serum total cholesterol (TC) and relaxation of the isolated aortic ring preparations by ACh. Treatment of cholesterolfed rats group (3) significantly (p< 0.05) increased SOD enzyme level, reduced the elevated SBP & serum total cholesterol (TC) and augmented relaxation responses to ACh compared to cholesterol-fed non-treated group (2). The effects of aliskiren were comparable to those reported with the control group (1).
• * p< 0.05 = significant decrease in SOD enzyme, while there is a significant increase in mean SBP, serum total cholesterol (TC) and significant reduction in relaxing effect of ACh in cholesterol-fed non-treated group (2) compared to control group (1)
• ** p< 0.05 = significant increase in SOD enzyme, while significant decrease in mean SBP, serum total cholesterol (TC) and significant augmentation in relaxing effect of ACh in aliskiren-treated group (3) compared to cholesterol-fed nontreated group (2).
Table 1: Mean ± SD of effect of treatment with aliskiren (5 mg/kg/day ip) on SOD enzyme, SBP, serum total cholesterol (TC) and relaxation of the isolated aortic ring preparations by ACh in all tested groups.